Extending Adjuvant GLIVEC Patient Image/Global

NEW TRIAL DATA

With 3 years of adjuvant therapy in KIT+ GIST patients, at 5-year analysis, GLIVEC provided1

92% OVERALL SURVIVAL
66% RECURRENCE-FREE SURVIVAL

LEARN MORE
GIST Risk Calculator

Gastrointestinal Stromal
Tumor (GIST)
Risk of Recurrence Calculator

Download this convenient interactive tool to quickly assess your patients risk of KIT+GIST recurrence, based on tumor size, tumor site, and mitotic rate.

GIST Recurrence Post Adjuvant Therapy Patient Image/Global

In advance disease,
GLIVEC EXTENDED OVERALL SURVIVAL TO

57 MONTHS
FROM 10 MONTHS2,3

LEARN MORE